Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one
 dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and
 expand immunogenicity and safety data to adults through age 65.
This is a Phase 2a, randomised, double-blind study in 300 adults to compare the safety and
 immunogenicity of OVX836 to QIV (Influvac TetraTM). One dose of OVX836 at two dose levels
 will be administered intramuscularly, in comparison to Influvac TetraTM, quadrivalent
 seasonal influenza sub-unit vaccine in healthy subjects aged 18-65 years.
Inclusion Criteria:

 1. Written informed consent.

 2. Healthy male or female subjects, as determined by medical history and medical
 examination.

 3. Between the ages of 18 and 65 years, inclusive.

 4. Reliable and willing to make themselves available for the duration of the study, and
 willing and able to follow study procedures.

 Exclusion Criteria:

 1. Subject with a body mass index (BMI) ≥35 kg/m² on the day of vaccination.

 2. Previous influenza vaccination within 6 months before the day of vaccination, or
 planned to receive during the study duration.

 3. Any known or suspected immunodeficient conditions.

 4. Past or current history of significant autoimmune diseases, as judged by the
 Investigator.

 5. Current history of significant uncontrolled medical illness such as diabetes,
 hypertension, heart, renal or hepatic diseases, as judged by the Investigator.

 6. Female subjects: pregnant, breast-feeding or of childbearing potential without
 appropriate contraceptive methods in place for 2 months before enrolment, or with
 positive pregnancy test on the day of vaccination. Appropriate contraceptive methods
 are defined by the Clinical Trial Facilitation Group [CTFG] as follow: "Contraceptive
 methods that can achieve a failure rate of less than 1% per year when used
 consistently and correctly are considered as highly effective birth control methods.
 Such methods include: combined (estrogen- and progestogen-containing) hormonal
 contraception associated with inhibition of ovulation (oral, intravaginal,
 transdermal), progestogen-only hormonal contraception associated with inhibition of
 ovulation (oral, injectable, implantable intrauterine device, intrauterine
 hormone-releasing system), bilateral tubal occlusion, vasectomized partner and/or
 sexual abstinence (refraining from heterosexual intercourse)."

 7. Having received another vaccination within 3 months prior to the day of study
 vaccination for live attenuated vaccines, or within 1 month prior to the day of study
 vaccination for inactivated vaccines.

 8. Planning to receive other vaccines during the first 28 days following the study
 vaccine administration.

 9. Administration of any investigational or non-registered drug or vaccine within 3
 months prior to the administration of study vaccines, or planned administration of any
 such product during the whole study period.

 10. History of receiving blood, blood components or immunoglobulins within 3 months prior
 to the day of vaccination, or planned to receive such product during the whole study
 period.

 11. Presence of an acute febrile illness on the day of vaccination (oral temperature
 >38.0°C, temporary exclusion criterion).

 12. Past or current history of any progressive or severe neurological disorder, seizure
 disorder or Guillain-Barré syndrome.

 13. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the
 Investigator, may interfere with the subject's ability to participate in the study.

 14. Past (stopped less than 6 months before enrolment) or current history of alcohol or
 drug abuse, or current smoking habit above 10 cigarettes per day.

 15. Treatment that can affect immune response such as systemic or high dose inhaled
 corticosteroids (>800 μg/day beclomethasone or equivalent; occasional inhaled
 corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs,
 or current or recent (within 30 days before study entry) chronic or prolonged (>10
 days) use of systemic non-steroidal anti-inflammatory drugs, interferon,
 immunomodulators, allergy shots, as judged by the Investigator.

 16. Subjects with known or suspected anemia.

 17. Recent blood or platelets donation (less than 3 months before enrolment). History of
 plasma donation is authorized.

 18. History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions
 to vaccines or allergy to kanamycin, or to any component that may be present in the
 comparator vaccine, as traces such as eggs (ovalbumin, chicken proteins),
 formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin.

 19. Any contraindication to intramuscular administration, as judged by the Investigator.

 20. Individuals with history of any illness that, in the opinion of the Investigator,
 might interfere with the results of the study or pose additional risk to the subjects
 due to participation in the study.

 21. Technical difficulties in the use of an e-diary.

 22. Sponsor employees or Investigator site personnel directly affiliated with this study,
 and their immediate families. Immediate family is defined as a spouse, parent, child
 or sibling, whether biological or legally adopted.